Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation

Table 3

Posttransplant variables by development of NODAT.

	NODAT−	NODAT+	Total	𝑃 value
	𝑁=186	𝑁=39	𝑁=225
One year
FPG (mg/dL)	98 ± 11.5	148 ± 50	106 ± 30	—
Hgb A1C	5.4 ± 0.3	6.3 ± 1.3	5.6 ± 0.7	—
BMI	27.1 ± 5.4	29.0 ± 6.9	27.5 ± 5.8	0.07
Tacrolimus level (ng/mL)	10.8 ± 3.2	11.3 ± 3.3	10.9 ± 3.2	0.4
Primary IS, 𝑁 (%)
Tacrolimus	170 (91.4)	33 (84.6)	203 (90.2)	0.74
Cyclosporine	6 (3.2)	2 (5.1)	8 (3.6)
Sirolimus	10 (5.4)	3 (7.7)	13 (5.8)
Other	0	1 (2.6)	1 (0.4)
Steroid-treated rejection	0.2 ±.48	0.2 ±.47	0.2 ±.48	0.75
Cumulative steroid dose, mg	2811 ± 1447	2732 ± 1407	2797 ± 1437	0.75
NODAT			39 (17.3)
IFG, 𝑁 (%)	36 (16)
Total abnormal glucose homeostasis, 𝑁 (%)			75 (33.3)

Continuous variables presented as means with standard deviation.
BMI: body mass index, FPG: fasting plasma glucose, Hgb A1C: Hemoglobin A1C, IFG: impaired fasting glucose, IS: immunosuppression, NODAT: new-onset diabetes after transplantation.